The Phase I Clinical Study to Evaluate the Pharmacokinetics of Dw1029M in Healthy Male Volunteer

Summary

1. Objective After single dose in healthy adults the capacity of the Group for DW1029M evaluate the pharmacokinetic characteristics. 2. Indication Diabetic kidney disease 3. Efficacy 1. Primary * AUClast, AUCinf, AUClast/D, AUCinf/D * Cmax, Cmax/D 2. Secondary * Tmax, t1/2, CL/F, Vz/F 4. Safety 1. Adverse Event Monitoring 2. V/S, EKG, Laboratory Test, P/E

Timeline

Start

2013-12

Primary completion

2013-12

Completion

2014-06

Drugs

Indications